GGT5

Across TCGA pan-cancer cohorts, GGT5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GGT5 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GGT5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GGT5 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

STAD, GBM, and LIHC are the cancer types where GGT5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.149	0.710	<.001	15	view →
GBM	OS	Median	All	0.026	0.416	<.001	12	view →
LIHC	DFS	Median	All	0.166	0.548	<.001	12	view →
LUSC	DFS	Median	All	1.000	0.653	.030	8	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GGT5–STAD (DFS)

Open the STAD breakdown →